Serum MicroRNAs Predict Isolated Rapid Eye Movement Sleep Behavior Disorder and Lewy Body Diseases

Marta Soto1,2, Alex Iranzo2,3, Sara Lahoz4,5

  • 1Laboratory of Parkinson Disease and Other Neurodegenerative Movement Disorders, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)-Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Spain.

Abstract

Insights

Serum microRNA (miRNA) signatures can predict Lewy body disease (LBD) development in individuals with isolated rapid eye movement sleep behavior disorder (IRBD). These 12 specific miRNAs show promise as early biomarkers for Parkinson

Area of Science:

  • Neuroscience
  • Genetics
  • Biomarker Discovery

Background:

  • Isolated rapid eye movement sleep behavior disorder (IRBD) is a known precursor to Lewy body diseases (LBDs), including Parkinson's disease (PD) and dementia with Lewy bodies (DLB).
  • Early identification of LBD risk in IRBD patients is crucial for timely intervention and management.
  • Understanding the molecular changes preceding LBD diagnosis is essential for developing predictive biomarkers.

Purpose of the Study:

  • To investigate serum microRNA (miRNA) deregulation in IRBD patients at different stages of LBD progression.
  • To assess the predictive performance of differentially expressed miRNAs for LBD development using machine learning.
  • To determine if miRNA profiles can antedate LBD diagnosis in individuals with IRBD.

Main Methods:

  • Genome-wide miRNA analysis and real-time quantitative PCR validation were employed.
  • Serum samples from IRBD patients (DaT-negative, DaT-positive, and phenoconverted to LBD) and controls were analyzed.
  • A longitudinal follow-up of the IRBD cohort over 26 months was conducted with three time-point serum samples.

Main Results:

  • Twelve specific miRNAs (let-7c-5p, miR-19b-3p, miR-140, miR-22-3p, miR-221-3p, miR-24-3p, miR-25-3p, miR-29c-3p, miR-361-5p, miR-425-5p, miR-4505, and miR-451a) showed sustained deregulation across the IRBD continuum.
  • Machine learning models based on these 12 miRNAs accurately discriminated between IRBD/LBD patients and controls (AUC 98%).
  • The identified miRNA biosignatures demonstrated significant predictive performance for LBD clinical outcomes.

Conclusions:

  • Specific serum miRNA biosignatures are promising progression biomarkers for IRBD patients at risk of developing PD or DLB.
  • These miRNA profiles hold potential for predicting clinical outcomes in IRBD, complementing existing diagnostic methods.
  • Further research into miRNA biomarkers in other at-risk populations is warranted.